Company Interview / Apiam's strategic shift to drive shareholder returns

Bruce Dixon from Apiam Animal Health (ASX: AHX) outlines the company's strategic priorities amidst industry challenges. He points out the competitive advantage of being the only listed company in a sector heading towards consolidation. Apiam aims to optimise operations by decentralising responsibilities to clinics.

Dixon also emphasises the need to enhance revenue generation, particularly targeting underperforming clinics in order to achieve a 15% return on capital. He dismisses cost-cutting as a primary focus, instead highlighting the potential for increased revenue and operational efficiency to improve margins.

Despite market speculation about acquisitions and potential takeovers, Dixon underscores a commitment to organic growth for the coming year. He acknowledges the high debt levels but sees the turnaround and profitability efforts as remedies to address this.

Long-term plans include considering acquisitions. All of which Dixon says will be done with shareholder returns in mind.